For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders ...
Genezen has opened its new process development and analytical lab for viral vector production. Genezen, a cell and gene therapy contract development and manufacturing organization, has officially ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
The use of viral vectors as gene delivery and vaccine vehicles has developed rapidly during the last two decades owing to several viral properties. Viruses can infect cells efficiently, often have a ...
Saratoga, CA (June 6, 2023) – Vector Flow, the digital transformation leader in physical security automation, is proud to announce a new partnership with Nedap, a Dutch multinational technology ...
This partnership provides vital technology to streamline training management and enterprise training logistics for one of the world’s largest law enforcement organizations. “For two decades, Vector ...
Saratoga, CA (June 6, 2023) – Vector Flow, the digital transformation leader in physical security automation, is proud to announce a new partnership with Nedap, a Dutch multinational technology ...